Glenmark Pharma ends higher on receiving USFDA nod for Calcipotriene Cream

Glenmark will market this product upon receiving final approval of its Calcipotriene Cream, 0.005% ANDA.

May 04, 2015 11:05 IST India Infoline News Service

Glenmark Pharmaceuticals advanced 2% to Rs. 908 on BSE after the company received tentative approval by the United States Food & Drug Administration (USFDA) for Calcipotriene Cream, 0.005 percent.
The stock has hit a high of Rs. 929 and a low of Rs. 828.
Glenmark will market this product upon receiving final approval of its Calcipotriene Cream, 0.005% ANDA.  The patents listed in the Orange Book for Dovonex® Cream are scheduled to expire on June 9, 2015.

Related Story